Effects of Elevated Serum Prolactin on Bone Mineral Density and Bone Metabolism in Female Patients With Schizophrenia: A Prospective Study
Abstract
OBJECTIVE: This study was designed to prospectively examine differential effects of sustained "high" and "low" serum prolactin levels on bone mineral density and peripheral markers of bone metabolism. METHOD: A dual-energy X-ray absorptiometer was used to measure bone mineral density. Peripheral markers of bone formation and resorption were used to measure bone metabolism in 14 Caucasian female patients with schizophrenia treated with risperidone or olanzapine monotherapy over 12 months. RESULTS: Analyses of variance failed to show an association between elevated prolactin and bone mineral loss over time. However, higher rates of bone formation and resorption were seen in those with high prolactin levels. CONCLUSIONS: The results failed to show that elevated prolactin accelerates bone mineral density loss. However, sustained hyperprolactinemia did have an impact on the rate of bone metabolism. Perhaps higher prolactin levels over longer time periods are necessary before the metabolic processes become uncoupled, leading to bone mineral density loss.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies found a relationship between the use of prolactin-raising medication and low bone mineral density in patients with chronic schizophrenia, while others failed to find a relationship between prolactin, antipsychotics and osteoporosis.
“Some studies (490-493) found a relationship between the use of prolactin-raising medication and low BMD in patients with chronic schizophrenia, while others (474,489,494-498) failed to find a relationship between prolactin, AP and osteoporosis.”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [494]
Cites
Decreased Bone Density in Hyperprolactinemic Women
Klibanski, A., Neer, R. M., Beitins, I. Z., Ridgway, E. C., Zervas, N. T., & McArthur, J. W. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032605 · Cited by 358 · see citing works
Osteoporosis in Men with Hyperprolactinemic Hypogonadism
Greenspan, S. L., NEER, R. M., Ridgway, E. C., & KLIBANSKI, A. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-777 · Cited by 249 · see citing works
Accelerated Osteoporosis in Psychiatric Patients: Possible Pathophysiological Processes
Halbreich, U. M., & Palter, S. F. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.3.447 · Cited by 119 · see citing works
Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response
Meltzer, H. Y., Busch, D. A., & Fang, V. S. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90001-x · Cited by 54 · see citing works
Osteoporosis and schizophrenia: Can we limit known risk factors?
Abraham, G., Friedman, R. H., Verghese, C., & de Leon, J. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00062-l · Cited by 40 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488 · see citing works
Physical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633 · see citing works
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307 · see citing works
Gender Differences in the Prescribing of Antipsychotic Drugs
Seeman, M. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1324 · Cited by 237 · see citing works
Byerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815ac4e5 · Cited by 153 · see citing works
Gender Differences in the Prescribing of Antipsychotic Drugs
Seeman, M. V. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.1.115 · Cited by 145 · see citing works
Attachment and externalizing disorders: a developmental psychopathology perspective
GUTTMANN-STEINMETZ, S., & CROWELL, J. A. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000196422.42599.63 · Cited by 137 · see citing works
Prevalence of Hyperprolactinemia in Schizophrenia
Montgomery, J., Winterbottom, E., Jessani, M., Kohegyi, E., Fulmer, J., Seamonds, B., & Josiassen, R. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1108 · Cited by 130 · see citing works
Self-citationO'Keane, V. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088439 · Cited by 126 · see citing works
Osteoporosis and fracture risk in people with schizophrenia
Kishimoto, T., Binder, M. D., Carlson, H. E., Manu, P., & Correll, C. U. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328355e1ac · Cited by 116 · see citing works
Kerwin, R. W., Millet, B., Herman, E., Bánki, C. M., Lublin, H., Pans, M., Hanssens, L., L'Italien, G. J., McQuade, R. D., & Beuzen, J. N. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.03.002 · Cited by 111 · see citing works
Roke, Y., van Harten, P. N., Boot, A. M., & Buitelaar, J. K. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0120 · Cited by 108 · see citing works
Sex-Specific Differences in Side Effects of Psychotropic Drugs: Genes or Gender?
Haack, S., Seeringer, A., Thürmann, P., Becker, T. M., & Kirchheiner, J. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.102 · Cited by 101 · see citing works
Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood
Saeedi, H., Remington, G., & Christensen, B. K. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.033 · Cited by 89 · see citing works
Binder, M. D., Detraux, J., & Stubbs, B. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1167873 · Cited by 79 · see citing works
Safety and tolerability of emerging pharmacological treatments for bipolar disorder
Dünner, D. L. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00235.x · Cited by 69 · see citing works
Howes, O. D., Wheeler, M. J., Meaney, A.-M., O'Keane, V., Fogelman, I., Blake, G., Murray, R. M., & Smith, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162798.87249.4d · Cited by 64 · see citing works
Miller, S. C., & Bowman, B. M. (2007) · The Anatomical Record · doi:10.1002/ar.20403 · Cited by 60 · see citing works
Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences
Chen, C., Lane, H., & Lin, C. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.3.238 · Cited by 56 · see citing works
Bone Mineral Density in Schizophrenia
Tseng, P., Chen, Y., Yeh, P., Tu, K.-Y., Cheng, Y., & Wu, C.-K. (2015) · Medicine · doi:10.1097/md.0000000000001967 · Cited by 55 · see citing works
Diagnosis and management of hyperprolactinemia: expert consensus – French Society of Endocrinology
Brue, T. C., & Delemer, B. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2006.11.001 · Cited by 51 · see citing works
de Kuijper, G. M., Mulder, H., Evenhuis, H. M., Scholte, F. A., Visser, F. E., & Hoekstra, P. J. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.05.016 · Cited by 50 · see citing works
Osteoporosis, Schizophrenia and Antipsychotics
Halbreich, U. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00003 · Cited by 45 · see citing works
Physical Illness and Schizophrenia
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511543951 · Cited by 45 · see citing works
Bone Loss Associated with Hyperprolactinemia in Patients with Schizophrenia
Kinon, B. J., Liu‐Seifert, H., Stauffer, V. L., & Jacob, J. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.kise.020113 · Cited by 44 · see citing works
Emerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles
Marken, P. A., & Pies, R. W. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g112 · Cited by 44 · see citing works
Roke, Y., van Harten, P. N., Buitelaar, J. K., Tenback, D. E., Quekel, L. G. B. A., de Rijke, Y. B., & Boot, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0521 · Cited by 43 · see citing works
Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents
Calarge, C. A., Ivins, S. D., Motyl, K. J., Shibli-Rahhal, A. A., Bliziotes, M. M., & Schlechte, J. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313487548 · Cited by 39 · see citing works
Bone Density in Chronic Schizophrenia with Long-Term Antipsychotic Treatment: Preliminary Study
Lee, T. Y., Chung, M.-Y., Chung, H.-K., Choi, J., Kim, T. Y., & So, H. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.4.278 · Cited by 38 · see citing works
High bone turnover but normal bone mineral density in women suffering from schizophrenia
Bergemann, N., Parzer, P., Mundt, C., & Auler, B. (2008) · Psychological Medicine · doi:10.1017/s003329170800319x · Cited by 37 · see citing works
Chamouni, A., Schreiweis, C., & Oury, F. (2015) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-015-9312-5 · Cited by 37 · see citing works
Kirino, E. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0166-y · Cited by 35 · see citing works
Takahashi, T., Uchida, H., John, M., Hirano, J., Watanabe, K., Mimura, M., Correll, C. U., & Kishimoto, T. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.04.015 · Cited by 34 · see citing works
Weaning Initiates a Rapid and Powerful Anabolic Phase in the Rat Maternal Skeleton1
Miller, S. C., Anderson, B., & Bowman, B. M. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.039610 · Cited by 31 · see citing works
Ak, E., Bulut, S. D., Bulut, S., Akdağ, H. A., Oter, G., Kaya, H., Kaya, O. B., Sengul, C. B., & Kısa, C. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2859-2 · Cited by 30 · see citing works
Zhang, B., Deng, L., Wu, H., Lu, X., Peng, L., Wu, R., Guo, W., Chen, J., Li, L., & Zhao, J. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.034 · Cited by 31 · see citing works
Bone Mineral Density in Male Schizophrenia Patients: A Review
Meyer, J. M., & Lehman, D. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230500464687 · Cited by 29 · see citing works
Second-generation antipsychotics and bone turnover in schizophrenia
Okita, K., Kanahara, N., Nishimura, M., Yoshida, T., Yasui‐Furukori, N., Niitsu, T., Yoshida, T., Ishikawa, M., Kimura, H., Nomura, F., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.05.009 · Cited by 28 · see citing works
Jung, D.-U., Seo, Y.-S., Park, J.-H., Jeong, C.-Y., Conley, R. R., Kelly, D. L., & Shim, J.-C. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186738.84276.9f · Cited by 25 · see citing works
No association between bone mass and prolactin levels among patients with schizophrenia
Sugawara, N., Yasui‐Furukori, N., Fujii, A., Saito, M., Sato, Y., Nakagami, T., Tsuchimine, S., & Kaneko, S. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1250 · Cited by 23 · see citing works
Clozapine protects bone mineral density in female patients with schizophrenia
Lin, C., Huang, K.-H., Chang, Y., Huang, Y., Hsu, W.-C., Lin, C.-Y., Chou, F. H., Tsai, G. E., & Lane, H. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001507 · Cited by 22 · see citing works
Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment
Bishop, J. R., Rubin, L. H., Reilly, J. L., Pavuluri, M. N., & Sweeney, J. A. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312442080 · Cited by 20 · see citing works
Incidence and prevalence of medication-induced osteoporosis: evidence-based review
Allport, J. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282ff0d6d · Cited by 20 · see citing works
Trial of aripiprazole in the treatment of first‐episode schizophrenia
Lee, H., Ham, B., Kang, R.-H., Paik, J., Hahn, S., Lee, M., & Lee, M. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.02039.x · Cited by 19 · see citing works
Diethylstilbesterol has Gender-Specific Effects on Weight Gain and Bone Development in Mice
Kaludjerovic, J., & Ward, W. E. (2008) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390801988947 · Cited by 19 · see citing works
Bulut, S. D., Bulut, S., Atalan, D. G., Tulacı, R. G., Türker, T., Gürçay, E., & Aydemir, Ç. (2016) · PubMed · Cited by 19 · see citing works
Treatment Considerations in Women with Schizophrenia
Kelly, D. L. (2006) · Journal of Women s Health · doi:10.1089/jwh.2006.15.1132 · Cited by 19 · see citing works
Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia
Lin, C., Lin, C.-Y., Wang, H.-S., & Lane, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40691-7 · Cited by 18 · see citing works
Renn, J.-H., Yang, N.-P., & Chou, P. (2010) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-11-35 · Cited by 17 · see citing works
Hip, vertebral, and wrist fracture risks and schizophrenia: a nationwide longitudinal study
Chu, Y.-W., Chen, W., Yang, A. C., Tsai, S., Hu, L., Lee, S.-C., Lee, Y., & Shen, C. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03723-7 · Cited by 16 · see citing works
Marano, R. J., Tickner, J. C., & Redmond, S. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063952 · Cited by 15 · see citing works
Bone mineral density measurement in female inpatients with schizophrenia
Kishimoto, T., Watanabe, K., Takeuchi, H., Kikuchi, T., Nakajima, S., Shimada, N., Yagi, G., & Kashima, H. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.011 · Cited by 14 · see citing works
Zhang, Y., Deng, L., Fan, J., & Ya-zhi, Z. (2020) · Cellular and Molecular Biology · doi:10.14715/cmb/2020.66.5.17 · Cited by 13 · see citing works
Bone phenotypes in multiple endocrine neoplasia type 1: survey on the MEN1 Florentine database
Marini, F., Giusti, F., Iantomasi, T., Cioppi, F., & Brandi, M. L. (2022) · Endocrine Connections · doi:10.1530/ec-21-0456 · Cited by 12 · see citing works
van der Leeuw, C., Habets, P., Domen, P. A. E., van Kroonenburgh, M. J. P. G., van Os, J., & Marcelis, M. C. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.031 · Cited by 11 · see citing works
van Kooten, M., Arends, J., & Cohen, D. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318205e1aa · Cited by 11 · see citing works
Sackett, G. P., Unis, A. S., & Crouthamel, B. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0018 · Cited by 11 · see citing works
Bulut, S. D., BULUT, S., Tüzer, V., Ak, M., Ak, E., Kısa, C., Aydemir, Ç., & Göka, E. (2014) · Nöro Psikiyatri Arşivi · doi:10.4274/npa.y6628 · Cited by 10 · see citing works
Brue, T. C., & Delemer, B. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.02.006 · Cited by 8 · see citing works
Qiu, J., Gong, H., Wang, B., Gu, W., Wang, L., Gu, M., Zhang, Y., & Du, X. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00771-y · Cited by 7 · see citing works
de Kuijper, G. M., Mulder, H., Evenhuis, H. M., Visser, F. E., & Hoekstra, P. J. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182a60848 · Cited by 7 · see citing works
Shen, S., Liu, Y., Qiu, H., Tsai, K., Wu, H., Liang, W., Shu, M., & Chou, F. H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221948 · Cited by 7 · see citing works
Liang, Y., Su, Y.-A., Zhao, Z.-G., Gao, N., Huang, J.-Z., Tang, M.-Q., Li, K.-Q., Yang, F.-D., Yu, X., & Si, T.-M. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000379 · Cited by 6 · see citing works
Managing Psychotic Illness in Young People: A Practical Overview
Tiffin, P. A. (2006) · Child and Adolescent Mental Health · doi:10.1111/j.1475-3588.2006.00418.x · Cited by 6 · see citing works
Low bone density with the use of valproate
Waheed, A., & Kettl, P. A. (2005) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2005.03.008 · Cited by 6 · see citing works
van der Leeuw, C., Peeters, S. C. T., Domen, P. A. E., van Kroonenburgh, M. J. P. G., van Os, J., Marcelis, M. C., & (G.R.O.U.P.), G. R. A. O. I. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136320 · Cited by 5 · see citing works
Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
Riecher‐Rössler, A., Schmid, C., Bleuer, S., & Birkhäuser, M. (2009) · Gynäkologische Endokrinologie · doi:10.1007/s10304-009-0316-7 · Cited by 5 · see citing works
Proinflammatory Activation of Osteoclasts Due to High Prolactin Level
Saeed, Z. F., Kadhim, B. A., Al-Yasari, A. M. R., Kheder, R. K., Abdulhussein, S. A., James, H., & Alsaadawi, M. A. (2022) · Iraqi Journal of Science · doi:10.24996/ijs.2022.63.12.8 · Cited by 3 · see citing works
Josiassen, R. C., Xavier, R. M., Dietterich, T. E., Harner, M. K., Filmyer, D. M., Houpt, C., Lichtenstein, M. L., Farrell, M. S., Shaughnessy, R. A., Lázaro‐Muñoz, G., et al. (2025) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaf019 · Cited by 3 · see citing works
Self-citationKronik Antipsikotik Kullanımının Kemik, Meme ve Serviks Üzerine Etkileri
Bilici, M., Yenel, A., Kavlak, S. Ö., Uz, Y., Sünbül, E. A., & Çiftçi, A. (2011) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20110510114010 · Cited by 2 · see citing works
Miller, S. C., & Bowman, B. M. (2006) · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · doi:10.1002/ar.a.20403 · Cited by 2 · see citing works
Effectiveness of Quetiapine in Outpatients With Schizophrenia Assessed Under "Real-Life" Conditions
Riedel, M. J., Severus, E., Schennach-Wolff, R., Musil, R., Spellmann, I., Oppolzer, B., Möller, H., Köhler, J., & Seemüller, F. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182061184 · Cited by 1 · see citing works
Antipsychotic therapies and bone health
Paschou, S. Α., Mentzelopoulos, P., & Lambrinoudaki, I. V. (2019) · Case Reports in Women s Health · doi:10.1016/j.crwh.2019.e00160 · Cited by 1 · see citing works
van der Leeuw, C. (2015) · doi:10.26481/dis.20150623cl · Cited by 1 · see citing works
Wpływ flufenazyny i risperidonu na przebudowę kości u szczurów owariektomizowanych
Pytlik, M., & Fronczek-Sokół, J. (2012) · Annales Academiae Medicae Silesiensis
Hyperprolactinaemia: metabolic consequences
Kostrzak, A. (2014)
Physical Activity and Quality of Life of Outpatients with Schizophrenia
Gomes, E. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/rp0s-8s94
Maj, M., Ïðåçèäåíò, È., Tasman, A., & Herrman, H. (2011)
Kerwin, R. W., Millet, B., Herman, E., Bánki, C. M., Lublin, H., Pans, M., Hanssens, L., L'Italien, G. J., McQuade, R. D., & Beuzen, J. N. (2008) · European psychiatry (Ed Española) · doi:10.1017/s1134066500004288
Шуб, Г. М., Владимирович, А. В., Сергеевич, Л. М., Добрейкин, Е. А., Алипов, Н. В., Александровна, П. Е., Raikova, S. V., & Георгиевна, Ш. О. (2011) · DOAJ (DOAJ: Directory of Open Access Journals)
Wang, F., Li, H., Yi, K., Yan, W. S., Bian, Q., Guo, B., Luο, X., Kang, Y., Wu, Q., & Ma, Q. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06592-y
- Authors
- Abraham, G., Paing, W. W., Kaminski, J., Joseph, A., Kohegyi, E., & Josiassen, R. C.
- Venue
- American Journal of Psychiatry
- Published
- 2003-09-01
- Volume
- 160
- Issue
- 9
- Pages
- 1618-1620
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2010510096
- Cited by
- 82
- References
- 5
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 3 · 2020: 2 · 2019: 3 · 2017: 1 · 2016: 4 · 2015: 6 · 2014: 4 · 2013: 7 · 2012: 5
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- hyperprolactinemia, serum prolactin, bone mineral density, bone metabolism, bone formation, bone resorption, schizophrenia, female patients, risperidone, olanzapine, antipsychotic adverse effects
- MeSH terms
- Adult, Analysis of Variance, Bone and Bones, Bone Resorption, Female, Humans, Hyperprolactinemia, Middle Aged, Osteogenesis, Prolactin, Prospective Studies, Risk Factors, Schizophrenia, Antipsychotic Agents, Biomarkers, Absorptiometry, Photon, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
